Please login to the form below
myelofibrosis
This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future
The companies are also developing luspatercept for the treatment of myelofibrosis.
Latest news
-
CTI slumps as Servier-partnered lymphoma drug fails
CTI slumps as Servier-partnered lymphoma drug fails. After major setback CTI, has promising myelofibrosis candidate to fall back on. ... If approved, it will compete with Incyte and Novartis' Jakafi (ruxolitinib) in myelofibrosis, which is predicted to
-
Another R&D flop for Incyte, but Jakafi keeps delivering
Jakafi is marketed by Incyte in the US and by Novartis (as Jakavi) in other markets, for polycythemia vera and myelofibrosis. ... after a less-than-optimal FDA approval, and data suggesting that myelofibrosis patients treated with Jakafi may be at
-
Daily Brief
Another drug price sampled was Novartis’myelofibrosis treatment Jakavi. The algorithm judges that a fair price would be $17, 251 per treatment, far below the UK ($59, 760) and US ($90,
-
FDA turns down Celgene’s filing for multiple sclerosis drug
$7bn for Impact Biomedicines to add late-stage candidate fedratinib for myelofibrosis and polycythemia vera.
-
Is acquisitive Celgene now eyeing CAR-T specialist Juno?
inhibitor - fedratinib - in development for myelofibrosis and polycythaemia vera.
More from news
Approximately 8 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other indications could amount to $1.4bn. ... Acquisition company - remaining 90%. 9, 000. Impact
-
Pharma deals in August 2015
Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.
-
Pharma deals during November 2014
Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal
-
NICE and ‘ultra orphans’
It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,
-
Pharma deals during November 2013
Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and certain solid tumours.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Boston Biomedical appoints commercial head
At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
THE OTHER SIDE OF...BLOOD CANCER
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
-
THE OTHER SIDE OF...BLOOD CANCER
He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called myelofibrosis.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary is DOE
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Systematic Review Lead- London
-
Negotiable
-
Sudler London - Account Director
-
Competitive
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Medical Writers Required - Hertfordshire
-
Competitive
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
Subscribe to our email news alerts
- Lucid limbers up for second annual sports day
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- Hanover Health launches award, Firstlight spins off healthcare arm and more
- J&J files ‘breakthrough’ bladder cancer drug in US
- Boehringer’s Corsico to be new GSK drug dev leader
- More tell, less sell: HCP-centric comms
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
